Informazioni
Non ci sono recensioni
Lipoprotein Physiology
Pages 1-12
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Dyslipidemias
Pathophysiology, Evaluation and Management
Garg
Editore
Springer
Anno
2015
Pagine
525
ISBN
9781607614234
190,00 €
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.
-
-
Epidemiology of Blood Lipids and Lipoproteins
Pages 13-24
-
Lipoprotein(a)
Pages 25-55
-
Lipoproteins and Cardiovascular Disease Risk
Pages 57-65
-
Detection and Treatment of Children and Adolescents with Dyslipidemia
Pages 67-97
-
Type 2 Diabetes Mellitus and Dyslipidemia
Pages 99-113
-
Type 1 Diabetes Mellitus and Dyslipidemia
Pages 115-135
-
Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome
Pages 137-154
-
Dyslipidemia in HIV-Infected Patients
Pages 155-176
-
Monogenic Hypercholesterolemias
Pages 177-203
-
Primary Hypertriglyceridemia
Pages 205-220
-
Genetic Disorders of HDL Metabolism
Pages 221-233
-
Sitosterolemia and Other Rare Sterol Disorders
Pages 235-250
-
Genetic Abetalipoproteinaemia and Hypobetalipoproteinaemia
Pages 251-266
-
Drug-Induced Dyslipidemia
Pages 267-286
-
Lipodystrophies and Dyslipidemias
Pages 287-302
-
Novel Genes for Dyslipidemias: Genome-Wide Association Studies
Pages 303-312
-
Perspectives on Cholesterol Guidelines
Pages 313-327
-
Nutrition and Coronary Heart Disease Prevention
Pages 329-341
-
Phytosterol Therapy
Pages 343-354
-
Pages 355-370
-
Polyphenols for Cholesterol Management
Pages 371-382
-
Dietary Supplements for Cholesterol Management
Pages 383-402
-
Statins: Risk-Benefits and Role in Treating Dyslipidemias
Pages 403-421
-
Fibrates: Risk Benefits and Role in Treating Dyslipidemias
Pages 423-438
-
Niacin: Risk Benefits and Role in Treating Dyslipidemias
Pages 439-452
-
Bile Acid Sequestrants: Risk–Benefits and Role in Treating Dyslipidemias
Pages 453-463
-
Cholesterol Absorption Inhibitor Ezetimibe: Risk–Benefits and Role in Treating Dyslipidemias
Pages 465-481
-
Low-Density Lipoprotein (LDL) Apheresis
Pages 483-497
-
Novel Lipid-Lowering Agents
Pages 499-519
